ArticleThoracic cancer2022

Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.

Masaki Ishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.